Secukinumab (anti-IL-17A)

製品コード：A2025         Batch: A202501

印刷

Secukinumab (anti-IL-17A) (Cosentyx, AIN457) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is applied for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. MW=147.9 kDa.

製品説明

CAS No. 1229022-83-6
Formulation PBS buffer, pH 7.2
Isotype Human IgG1
Source Human
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Purity 99.82%
Protein concentration 5.00mg/ml
Endotoxin Level <1EU/mg

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Overexpression of microRNA-145 enhanced docetaxel sensitivity in breast cancer cells via inactivation of protein kinase B gamma-mediated phosphoinositide 3-kinase -protein kinase B pathway [ Signal Transduct Target Ther, 2022, 7(1):80] PubMed: 35301282
Hepatic interferon regulatory factor 8 expression mediates liver ischemia/reperfusion injury in mice [ Biochem Pharmacol, 2021, 192:114728] PubMed: 34400126

人間や獣医の診断であるか治療的な使用のためにでない。